bg content top home

Smarter science.
Better health.


RDD Pharma, a leader in developing treatments for anorectal disorders, announces the patent covering methods for treating fecal incontinence has been granted in Israel. The patent is based on the increase in resting anal pressure via a topical administration of RDD-0315, an alpha-agonist.  Patents have already been granted in EU, China and Russia and are pending in U.S., Japan, Australia, Brazil, Canada, and India.

RDD Pharma has also received a notice of allowance in the EU for methods and devices for delivery of pharmaceutical agents related to the Capository™, adding to granted patents in the U.S. and Israel.  RDD-1219, using the Capository™, is currently in Phase 3 development in Europe for the treatment of pain associated with chronic anal fissure.

About RDD-0315 and Fecal Incontinence: RDD-0315 is being developed for the treatment of fecal incontinence.  A successful Phase 2a study in spinal cord injury patients has been completed in the EU and continued development is ongoing in the US. An estimated 20 million adults suffer from fecal incontinence in the U.S.  With limited treatment options, RDD-0315 offers a promising Rx solution to address a large unmet need.

About RDD-1219 and Chronic Anal Fissure: RDD-1219 Capository™ has the potential to provide pain relief and to promote healing of the extremely painful and difficult to treat condition of chronic anal fissure.  There are an estimated 235,000 new cases of anal fissure reported every year in the US, and about 40% of them persist for months and even years. M.H. Madalinski. World J Gastrointestinal Pharmacology Ther 2011 April 6; 2(2): 9-16


Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.



Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.



Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).



Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.


Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2016, RDD Pharma, Ltd. All rights reserved.


Go to top